A share price of Xenon Pharmaceuticals Inc [XENE] is currently trading at $35.11, up 3.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XENE shares have gain 14.25% over the last week, with a monthly amount glided 0.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xenon Pharmaceuticals Inc [NASDAQ: XENE] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $67. On October 01, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $53 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $62 on January 04, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $63 as its price target on December 08, 2023. In a note dated April 25, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $58 on this stock.
Xenon Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $26.74 and $46.00. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $35.11 at the most recent close of the market. An investor can expect a potential return of 19.62% based on the average XENE price forecast.
Analyzing the XENE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.29 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.75 points at the first support level, and at 32.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.94, and for the 2nd resistance point, it is at 36.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xenon Pharmaceuticals Inc [NASDAQ:XENE] is 17.85. As well, the Quick Ratio is 17.85, while the Cash Ratio is 4.01.
Transactions by insiders
Recent insider trading involved MORTIMER IAN, PRESIDENT & CEO, that happened on Jan 24 ’25 when 22468.0 shares were sold. PRESIDENT & CEO, MORTIMER IAN completed a deal on Jan 27 ’25 to sell 16315.0 shares. Meanwhile, PRESIDENT & CEO MORTIMER IAN sold 16217.0 shares on Jan 23 ’25.
